麝香保心丸治疗慢性心力衰竭的Meta分析

A meta-analysis of adding Shexiangbaoxin pills in treating patients with chronic heart failure

目的评价麝香保心丸治疗慢性心力衰竭的临床疗效。方法 2014年10月检索Pubmed、万方数据库、中国学术期刊全文数据库、中国生物医学文献数据库和维普数据库,按入选标准纳入麝香保心丸治疗慢性心力衰竭的随机对照临床试验,提取资料,应用Rev Man 4.2.2软件进行数据分析。结果入选31项随机对照临床试验共2596例患者,联合应用麝香保心丸治疗慢性心力衰竭的总有效率优于对照组（RR=1.18,95%CI：1.13～1.24,P〈0.01）;麝香保心丸组患者左室射血分数（LVEF）较对照组提高4.76%（95%CI：3.64～5.87,P〈0.01）,血清钠尿肽（BNP）水平较对照组显著降低;麝香保心丸组患者左室舒张末期内径（LVEDD）和左室收缩末期内径（LVESD）均显著减小;麝香保心丸组患者6min步行距离较对照组增加41.88 m（95%CI：33.39～50.37,P〈0.01）。结论联合应用麝香保心丸治疗慢性心力衰竭有助于进一步改善心功能,延缓心室重构的病理进程。

Objective To evaluate whether Shexiangbaoxin pills can improve the clinical efficacy in patients with chronicheart failure.Methods Studies were identified by search of PUBMED,WANFANG,CNKI,CBM,and VIP database（inception to October 2014）.A standardized protocol with inclusion criteria was used to extract data from published randomized controlled trials.Rev Man version 4.2.2 was used for this meta-analysis.Results Thirtyone randomized controlled trials involving 2596 patients were identified and included for analysis.The overall therapeutic effects were improved in theatment group compared with control group（RR = 1.18,95% CI： 1.13 ～ 1.24,P 0.01）.The left ventricular ejection fraction（LVEF） was increased 4.76%（95% CI： 3.64 ～ 5.87,P 0.01）,whereas serum brain natriuretic peptide（BNP）,left ventricular end-diastolic dimension（LVEDD）,and left ventricular endsystolic dimension（LVESD） were decreased significantly in treatment group.The 6-minute walk test（6MWT） increased 41.88 m associated with active treatments（95% CI： 33.39 ～ 50.37,P 0.01）.Conclusions Shexiangbaoxin pills can improve cardiac function and inhibit ventricular remodeling in patients with chronicheart failure.